Astrotech Corporation (NASDAQ: ASTC) — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended March 31, 2024 (Astrotech fiscal Q3 2024), not 2022 Q3 as stated in the request metadata. Financial amounts below are in millions unless otherwise noted.
Business context and reporting period
Astrotech develops and commercializes mass spectrometry technology through subsidiaries serving security detection, hemp and cannabis processing, breath analysis, and chemical manufacturing process control. This unaudited Form 10-Q reports the three and nine months ended March 31, 2024, compared with the same periods in 2023.
Financial performance
| Metric | Q3 FY2024 | Q3 FY2023 | Nine months FY2024 | Nine months FY2023 |
|---|---|---|---|---|
| Revenue | $0.050 | $0.035 | $1.590 | $0.336 |
| Gross profit (margin) | $0.008 (16%) | $0.011 (31%) | $0.723 (45%) | $0.125 (37%) |
| Operating expenses | $3.541 | $2.761 | $10.659 | $8.453 |
| Operating loss | $(3.533) | $(2.750) | $(9.936) | $(8.328) |
| Net loss | $(3.154) | $(2.375) | $(8.707) | $(7.322) |
| Loss per share | $(1.93) | $(1.47) | $(5.34) | $(4.54) |
For the nine-month period, operating cash outflow was $7.237 million, versus $6.340 million a year earlier. Investing activities provided $1.652 million, primarily reflecting short-term investment proceeds; financing used $0.136 million. Cash and cash equivalents fell $5.721 million to $8.487 million. At March 31, 2024, short-term investments were $26.196 million, total current assets $37.502 million, current liabilities $2.445 million, and working capital approximately $35.1 million. Total liabilities were $2.632 million, including lease liabilities; the filing reports no material off-balance-sheet arrangements. The prior related-party note had been repaid in 2022.
Changes versus comparable periods
- Quarterly revenue rose $15,000, or 42.9%, mainly from maintenance and consumables on deployed TRACER 1000 units. Quarterly gross margin declined from 31% to 16%, with shipping inflation cited.
- Nine-month revenue increased by $1.254 million, principally from TRACER 1000 unit sales fulfilling previously announced orders. Gross margin improved from 37% to 45%, attributed to design improvements, lower warranty expense, and higher comparative selling prices.
- Nine-month operating expenses increased $2.206 million: SG&A rose $0.895 million and R&D rose $1.311 million. Management cited sales-related legal and consulting costs, employee and director costs, increased development staffing, and product and platform development.
- Cash and cash equivalents declined from $14.208 million at June 30, 2023, while short-term investments declined from $27.919 million to $26.196 million. Total assets decreased to $40.203 million from $47.675 million.
Outlook, commentary, and risks
- No specific revenue or earnings guidance is provided. Management said there had been no material update to its liquidity and operating-capital expectations since the fiscal 2023 Form 10-K. It expects a 0% effective tax rate for fiscal 2024; deferred tax assets are fully reserved.
- TRACER 1000 sales remain dependent on customer demand and regulatory progress. TSA cargo detection testing resumed in fiscal Q3 2024; it is described as the final step toward the Air Cargo Screening Technology List approved-device status. U.S. checkpoint testing is also in process. Neither outcome is assured.
- The company reported deployments in approximately 30 locations across 14 countries. It announced orders for 14 units and a separate order for seven units, which it says were delivered. It began accepting orders for a narcotics detector; the TRACER 1000 was also added to a GSA purchasing schedule after quarter-end.
- AgLAB and Pro-Control products are being marketed or developed, and BreathTech is conducting disease-screening research with Cleveland Clinic. Commercial adoption and technical results remain uncertain.
- Revenue is highly concentrated: one customer represented materially all quarterly revenue in Q3 FY2024; three customers represented materially all nine-month revenue. A single company comprised a material portion of receivables.
- Management identifies risks including product-market acceptance, TSA certification and government funding, competition, development execution, supply availability and inflation, geopolitical and economic conditions, and evolving cannabis regulation. Supply-chain constraints and pricing inflation could adversely affect operations.
- The company reported no current litigation in the financial-statement notes and no material changes to the risk factors in its fiscal 2023 Form 10-K. Disclosure controls were assessed as effective as of March 31, 2024.
Important facts for investors to verify
- Confirm the reporting-period mismatch in the request metadata: the filing covers Q3 FY2024, ended March 31, 2024.
- Reconcile the MD&A statement that nine-month revenue increased “$1.3 million, or 3.7%” with the financial statements: revenue rose from $0.336 million to $1.590 million, approximately 373%.
- Monitor customer concentration, recurring consumables and service revenue, and whether new unit orders translate into sustained sales and cash receipts.
- Track TSA cargo and checkpoint testing milestones, certification decisions, and any resulting U.S. commercial orders.
- Assess cash consumption, investment liquidity, and the ability to fund continuing operating and product-development costs.